Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of WPV01 +/- Ritonavir in Healthy Subjects
NCT06205329Phase 1Completed
- Sponsor
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
- Start
- Oct 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of iscartrelvir in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Westlake Pharmaceuticals (Hangzhou) Co., Ltd. Primary endpoint: Safety and Tolerability. Started Oct 2022; status: completed.
02
Drugs
iscartrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06205329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06205329.